Ulf Jungnelius, MD

Education/Background:  Oncology Specialist with a diploma from Karolinska Institute, along with clinical experience from Radiumhemmet in Stockholm. Dr. Jungnelius has extensive experience in international clinical research & development in the field of oncology. He has held executive positions at several international companies such as Eli Lilly, Pfizer, Takeda, and Celgene.

Current Assignments:  Henrik is CEO at Isofol Medical AB, a Board member at Oncopeptides AB, and CARPONOVUM AB.

Holdings:  25,000 TO4, 25,000 TO7, 25,000 TO10